Summary

Eligibility
for people ages 50-80 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 18 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).

Official Title

A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease

Keywords

Alzheimer's Disease, Early Alzheimer's Disease, E2814, Lecanemab, Alzheimer Disease

Eligibility

Locations

  • University of California at San Francisco/UCSF not yet accepting patients
    San Francisco California 94158-2549 United States
  • Sharp Neurocognitive Research Center at Sharp Mesa Vista Hospital not yet accepting patients
    San Diego California 92123 United States
  • Kerwin Medical Center accepting new patients
    Dallas Texas 75231-4350 United States
  • Washington University School of Medicine accepting new patients
    Saint Louis Missouri 63110 United States

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Eisai Inc.
ID
NCT06602258
Phase
Phase 2 Alzheimer's Disease Research Study
Study Type
Interventional
Participants
Expecting 90 study participants
Last Updated